Advertisement

Topics

FDA approves Imbruvica as first therapy for chronic graft-versus-host disease

12:35 EDT 2 Aug 2017 | Healio

The FDA approved ibrutinib for the treatment of adults with chronic graft-versus-host disease who failed prior systemic therapy.Ibrutinib (Imbruvica; Pharmacyclics, Janssen) — a Bruton’s tyrosine kinase inhibitor already indicated for treatment of certain patients with leukemia, lymphoma and Waldenstrom’s macroglobulinemia — is the first therapy specifically approved to treat chronic GVHD.

Original Article: FDA approves Imbruvica as first therapy for chronic graft-versus-host disease

NEXT ARTICLE

More From BioPortfolio on "FDA approves Imbruvica as first therapy for chronic graft-versus-host disease"

Quick Search
Advertisement